Stay updated on Switch Maintenance in Pancreatic Clinical Trial
Sign up to get notified when there's something new on the Switch Maintenance in Pancreatic Clinical Trial page.

Latest updates to the Switch Maintenance in Pancreatic Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe study record was revised to Phase Ib Open-Label, Multicenter, non-randomized design evaluating switch maintenance using AB154, AB122, and Sotigalimab in metastatic pancreatic cancer, with Massachusetts as a participating location. Eligibility criteria were updated to exclude germline BRCA mutations, and endpoints now include PFS2.SummaryDifference1%

- Check19 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check40 days agoChange DetectedPage revision label updated from v3.2.0 to v3.3.2.SummaryDifference0.0%

- Check47 days agoChange DetectedNotice about lapse in government funding and NIH/Center for Operations status was removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check61 days agoChange DetectedThe new screenshot shows minor layout adjustments and an updated last updated date, while core study details, eligibility criteria, endpoints, and enrollment remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check90 days agoChange DetectedAdded a government funding/status notice and updated version to v3.2.0; removed old v3.1.0 tag.SummaryDifference2%

- Check97 days agoChange DetectedUpdated version from v3.0.2 to v3.1.0 and added a contact phone number (617-632-6073).SummaryDifference0.1%

Stay in the know with updates to Switch Maintenance in Pancreatic Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Switch Maintenance in Pancreatic Clinical Trial page.